Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research

Data ReadoutpositivesirexatamabbevacizumabPositive

AI Analysis

Summary

Leap Therapeutics announced publication of DeFianCe study results in Clinical Cancer Research showing sirexatamab improved response, progression-free survival, and overall survival in DKK1-high second-line mCRC patients when combined with bevacizumab, establishing DKK1 as a predictive biomarker.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

DeFianCe study results published in peer-reviewed Clinical Cancer Research journal. Sirexatamab demonstrated improved response, progression-free survival, and overall survival in DKK1-high second-line mCRC patients when added to bevacizumab. DKK1 established as continuous quantitative biomarker predicting treatment benefit.

Importance:6/10

Sentiment:

0.70

sirexatamabDKK1 biomarkercolorectal cancersecond-line treatmentpublicationcombination therapy

Related Companies

$LPTX

Read the original article

Published by PR Newswire Biotech on August 12, 2026 11:00 AM

Read Original